Cin­gu­late prices a down­sized pub­lic of­fer­ing as IPO par­ty ap­pears to die down

A few months af­ter fil­ing its S-1, Cin­gu­late fi­nal­ly joined the biotech IPO crowd yes­ter­day — but it wasn’t greet­ed with quite the same fan­fare that oth­er life sci­ence com­pa­nies saw ear­li­er this year.

The Kansas-based biotech, fo­cused on cre­at­ing longer-act­ing AD­HD meds, priced 4.2 mil­lion shares at $6 apiece, rais­ing a mea­ger $25 mil­lion. That price was the low end of an al­ready re­vised range of $6 to $8.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER